HRT Financial LLC purchased a new position in shares of Amyris Inc (NASDAQ:AMRS) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 15,812 shares of the biotechnology company’s stock, valued at approximately $52,000.
A number of other large investors have also recently made changes to their positions in AMRS. Jane Street Group LLC acquired a new stake in Amyris during the 4th quarter valued at $48,000. Caption Management LLC acquired a new position in shares of Amyris in the fourth quarter worth about $50,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Amyris in the fourth quarter worth about $58,000. Intellectus Partners LLC boosted its holdings in shares of Amyris by 263.6% in the fourth quarter. Intellectus Partners LLC now owns 20,000 shares of the biotechnology company’s stock worth $67,000 after buying an additional 14,500 shares during the period. Finally, Balasa Dinverno & Foltz LLC boosted its holdings in shares of Amyris by 99.6% in the fourth quarter. Balasa Dinverno & Foltz LLC now owns 23,711 shares of the biotechnology company’s stock worth $79,000 after buying an additional 11,834 shares during the period. 36.69% of the stock is owned by hedge funds and other institutional investors.
In other news, Director L John Doerr purchased 2,832,440 shares of the company’s stock in a transaction dated Wednesday, April 24th. The shares were bought at an average price of $5.12 per share, with a total value of $14,502,092.80. Following the completion of the transaction, the director now directly owns 5,532 shares in the company, valued at approximately $28,323.84. The purchase was disclosed in a filing with the SEC, which is available through this link. Company insiders own 21.80% of the company’s stock.
Shares of AMRS stock traded down $0.11 during trading on Friday, hitting $4.75. 1,786,900 shares of the company were exchanged, compared to its average volume of 3,703,752. The stock has a market cap of $391.81 million, a P/E ratio of -1.88 and a beta of 0.29. Amyris Inc has a twelve month low of $1.87 and a twelve month high of $9.28.
Amyris (NASDAQ:AMRS) last posted its quarterly earnings results on Monday, March 18th. The biotechnology company reported ($1.07) EPS for the quarter, missing the consensus estimate of $0.44 by ($1.51). The company had revenue of $19.36 million for the quarter, compared to analyst estimates of $98.52 million. The business’s revenue for the quarter was down 76.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.61 EPS. On average, analysts predict that Amyris Inc will post -0.31 EPS for the current fiscal year.
Amyris Company Profile
Amyris, Inc, an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products.
Featured Article: Debt-To-Equity Ratio
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.